Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 9, 2006

Primary Completion Date

February 2, 2012

Study Completion Date

February 2, 2012

Conditions
Brain NeoplasmsMelanoma
Interventions
DRUG

Lomustine

Starting dose 30 mg/m\^2 by mouth daily on Day 1 and 29.

DRUG

Temozolomide

75 mg/m\^2 by mouth daily on Days 1 to 42.

DRUG

Thalidomide

200 mg/m\^2 by mouth daily.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER